Arvinas ARVN
Arvinas FY 2020: revenue $21.8M; diluted EPS −$3.02
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001564590-21-009857
- Document
- 10-K
- Exhibit 10.34
- Material contract
- Exhibit 10.35
- Material contract
- Exhibit 99.1
- Press release
Key figures from this report
These are the numbers Arvinas reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$21.8MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$119.3MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$3.02No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$588.4MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$89.8MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
- aTYR PHARMA ATYR public float $464M, Jun 30, 2025
- Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
- Theravance Biopharma TBPH public float $449M, Jun 30, 2025
- Myriad Genetics MYGN public float $494M, Jun 30, 2025